Modality
ASO
MOA
PARPi
Target
GPRC5D
Pathway
Proteasome
EoE
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
~Oct 2019
→ ~Jan 2021
Phase 3
~Apr 2021
→ ~Jul 2022
NDA/BLA
Oct 2022
→ Dec 2027
NDA/BLACurrent
NCT04695969
1,392 pts·EoE
2022-10→2027-12·Recruiting
1,392 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-261.7y awayPh3 Readout· EoE
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-12-26 · 1.7y away
EoE
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04695969 | NDA/BLA | EoE | Recruiting | 1392 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT |